Open Access

Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients

  • Authors:
    • Linying Shi
    • Yuan Zhang
    • Jing Zhang
    • Yuanfeng Gao
    • Jiamei Liu
    • Mulei Chen
    • Xinchun Yang
  • View Affiliations

  • Published online on: June 10, 2020     https://doi.org/10.3892/etm.2020.8865
  • Pages: 1337-1342
  • Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Levels of blood pre-albumin (PA) and N-terminal pro-B-type natriuretic peptide (NT-pro BNP) in elderly patients with chronic heart failure (CHF) and their clinical value in prognosis evaluation were explored. A total of 410 elderly patients aged ≥65 years hospitalized for CHF were enrolled. The concentrations of blood PA and NT-pro BNP, routine blood test and biochemistry indicators were determined and color Doppler echocardiography was performed. Additionally, the patients were followed up after discharge, and based on the occurrence of major adverse cardiac events (MACE), they were divided into MACE group and non-MACE group. MACE group had an older age and a higher level of plasma NT-pro BNP than non-MACE group (77.82±6.57) years vs. (76.39±6.18) years, and (8,864.52±9,718.36) pg/ml vs. (4,165.62+6,437.28) pg/ml (P<0.05), and the left ventricular ejection fraction and serum PA level in MACE group were lower than those in non-MACE group (P<0.05). According to the results of multivariate regression analysis, serum PA [odds ratio (OR)=0.242, 95% confidence interval (CI)=0.137-0.406, P<0.001] and plasma NT-pro BNP (OR=1.847, 95% CI=1.024-3.158, P=0.036) were independent risk factors for the occurrence of cardiac events during follow-up. Decline in PA level and elevation in NT-pro BNP level have a strong correlation with poor prognosis of elderly CHF patients, and they can be used for clinically evaluating disease conditions, guiding treatment and improving prognosis.
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shi L, Zhang Y, Zhang J, Gao Y, Liu J, Chen M and Yang X: Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients. Exp Ther Med 20: 1337-1342, 2020
APA
Shi, L., Zhang, Y., Zhang, J., Gao, Y., Liu, J., Chen, M., & Yang, X. (2020). Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients. Experimental and Therapeutic Medicine, 20, 1337-1342. https://doi.org/10.3892/etm.2020.8865
MLA
Shi, L., Zhang, Y., Zhang, J., Gao, Y., Liu, J., Chen, M., Yang, X."Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients". Experimental and Therapeutic Medicine 20.2 (2020): 1337-1342.
Chicago
Shi, L., Zhang, Y., Zhang, J., Gao, Y., Liu, J., Chen, M., Yang, X."Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients". Experimental and Therapeutic Medicine 20, no. 2 (2020): 1337-1342. https://doi.org/10.3892/etm.2020.8865